Bay Bridge, San Francisco, CA

Leadership

Setting The Direction

Management Team

Adam mendelsohn

Adam Mendelsohn, Ph.D.

CEO, Co-Founder, Chairman

Since founding Nano Precision Medical, Dr. Mendelsohn has served as its Chief Executive Officer and sets the strategic vision for the company.

Dr. Mendelsohn received his Ph.D. in bioengineering at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering, Class of 2011, during which he was awarded an NSF fellowship to perform research at Kyoto University, and published multiple peer-reviewed articles describing new treatment options for Type 1 diabetes through the immuno-isolated transplantation of insulin-producing cells under the direction of Professor Tejal A. Desai. While in graduate school, Dr. Mendelsohn served as the director for the Venture Innovation Program in Life Sciences, and completed his certificate in Management of Technology with the Haas School of Business.

Dr. Mendelsohn has served as a Technical Advisor to the Alfred E. Mann Institute for Biomedical Engineering at USC, a fellow of the Startup Leadership Program, the President of UCSF’s Graduate Division Alumni Association, and is currently a board member of the Maestro Foundation.

Lisa porter

Lisa Porter, M.D.

Chief Medical Officer

Dr. Porter has over 20 years of experience in developing medicines for metabolic diseases with a focus on bringing innovative therapies to patients with high unmet need. Before joining NPM she served as CMO, Metabolic Diseases for Eiger Biopharmaceuticals where she led clinical development for the orphan diseases postbariatric hypoglycemia and Hutchinson-Gilford Progeria Syndrome resulting in FDA breakthrough therapy designation for both programs. She has previously served as CMO for Dance BioPharma (now Aerami Therapeutics) and Vice President, Medical Development for Amylin Pharmaceuticals where she led the R&D efforts for the Amylin-Lilly Alliance culminating in the approval of the GLP-1 agonist Bydureon, the 1st once weekly treatment for Type 2 diabetes. Prior to joining Amylin, Dr. Porter held progressively increasing leadership positions at GlaxoSmithKline Pharmaceuticals with responsibilities for the clinical strategy for Avandia and early obesity compounds and Associate Medical Director for Zeneca Pharmaceuticals.

Dr. Porter earned a BS in Biology from the College of William & Mary, an MD from Duke University and completed fellowship training in Endocrinology and Hypertension at Brigham and Women’s Hospital.

Kayte fischer

Kayte Fischer, Ph.D.

COO, Co-Founder

Since founding Nano Precision Medical, Dr. Fischer has been the Chief Operations Officer (from 2019 on) and Chief Technology Officer (founding until 2019), coordinating technical development and scientific research with a larger strategic vision for the company.

Dr. Fischer completed her Ph.D. in the Therapeutic Micro and Nanotechnology Laboratory at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering, Class of 2010. Her award-winning research focused on novel adhesive properties of nanostructured materials in the context of gastrointestinal drug delivery. During her time in graduate school, Dr. Fischer completed the Management of Technology program through the Haas School of Business and the College of Engineering. She also has a designated emphasis in Nanoscale Science and Engineering and served as the president of the Berkeley Nanotechnology Club. Prior to attending graduate school, Dr. Fischer graduated with honors from the California Institute of Technology with a B.S. in Mechanical Engineering. Dr. Fischer previously sat on the Associate Board of the Alameda Health System Foundation.

Ben stedman

Ben Stedman

Vice President of Manufacturing

Mr. Stedman leads the manufacturing efforts at Nano Precision Medical as the company prepares for clinical trials.

Mr. Stedman brings 25 years of manufacturing experience with complex drug-device combination products including roles in manufacturing engineering, Six-Sigma, supply chain, program management, and outsourced contract manufacturing. Ben has served in roles of increasing responsibility over the course of his career, most recently as the Vice President of Manufacturing at Aerami Therapeutics / Dance Biopharm which is developing a nebulizing inhaler platform that included an insulin and a GLP-1 formulation. Earlier in his career, Ben was an Executive Director at Coherus Biosciences where he was responsible for clinical and commercial supply chain as the company prepared to launch the first biosimilar to Neulasta, an Associate Director at Nektar Therapeutics for several years leading up to and after the approval of Exubera, and as a Senior Manager of MAP Pharmaceuticals through Allergan’s $1B acquisition of the company. Ben began his career in semiconductor manufacturing and has experiences that translate to the NanoPortal production.

He received his B.S. degree in Manufacturing Engineering from Cal Poly, San Luis Obispo, is a Six-Sigma Black Belt, and recently completed his MBA.

Antwan gipson

Antwan Gipson

Vice President of Operations and Quality

Mr. Gipson works with the operations and quality systems efforts related to the NanoPortal Platform Technology at Nano Precision Medical.

Mr. Gipson brings over 20 years of industry experience in medical devices, pharmaceuticals, and combination products, including leadership roles in operations, manufacturing, engineering, logistics, and quality. He has developed several successful teams and participated in the development and market introduction of numerous products. Antwan has served in similar roles with both publicly traded companies and venture-backed start-ups such as Allergan, Tautona Group, Cohesion Technologies (acquired by Angiotech Pharm.), and Fuisz Technologies (acquired by Biovail Corp.).

Antwan earned his B.Sc. in Engineering from Northern Michigan University, prior to serving in the United States Navy honorably, and has an MBA (emphasis applied research) from Angelo State University-Texas; including post graduate work and professional certificates in Quality Engineering, Product Lifecycle Management, and Lean Manufacturing.

Ryan olf

Ryan Olf, Ph.D.

Vice President of Product Development

Dr. Olf received his B.S. and Ph.D degrees in Physics from Caltech and U.C. Berkeley, respectively. His doctoral research integrated techniques from a wide range of fields to develop novel methods for producing, manipulating, and imaging quantum gases. Dr. Olf and his colleagues applied these techniques to produce the lowest entropy, or “quietest” gas ever made, with a temperature just 0.0000000005 degrees above absolute zero, and to study the behavior of fundamental magnetic excitations of these gases. In his spare time, Dr. Olf has enjoyed igniting curiosity and driving discovery in students and future teachers as an instructor in the UC Berkeley School of Education, and in the general public, as a volunteer activity developer and facilitator at the Exploratorium.

After receiving his degrees, Dr. Olf joined Nano Precision Medical as a Senior Scientist where he led a range of process development and research efforts. Prior to joining the leadership team, he served NPM as a Principal Scientist, making essential technical, strategic, and operational contributions to the company’s research, manufacturing, and product development efforts.

Wouter roorda

Wouter Roorda, Ph.D.

Vice President of Chemistry and Intellectual Property

Dr. Roorda leads the analytical chemistry activities at Nano Precision Medical and heads up the development of the Intellectual Property portfolio of the company.

Dr. Roorda has more than 35 years of academic and industry experience with controlled drug delivery, medical devices, drug-device combinations, and drug- and protein-formulation. In his Ph.D. studies, he developed and characterized a hydrogel-based drug delivery technology from polymer synthesis to testing in human volunteers. At Alza Corporation, he developed a number of formulations for implantable drug delivery systems intended for low molecular weight drugs as well as macromolecules.

As a research scientist at Guidant Corporation, Dr. Roorda pioneered some of the earliest studies on the Xience V drug eluting stent program, and after the acquisition by Abbott Labs, he assumed responsibility for new product concept generation and additional IP portfolio development as a director of R&D for the endovascular division. For his work on the Xience V stent, he was awarded the Volwiler Outstanding Research Team award, the highest scientific team award at Abbott Laboratories.

Dr. Roorda has a Ph.D. from the University of Leiden, The Netherlands, and he is a registered Patent Agent. He is an inventor on 84 US patents.

Board Of Directors

Adam mendelsohn

Adam Mendelsohn, Ph.D.

CEO, Co-Founder, Chairman

Since founding Nano Precision Medical, Dr. Mendelsohn has served as its Chief Executive Officer and sets the strategic vision for the company.

Dr. Mendelsohn received his Ph.D. in bioengineering at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering, Class of 2011, during which he was awarded an NSF fellowship to perform research at Kyoto University, and published multiple peer-reviewed articles describing new treatment options for Type 1 diabetes through the immuno-isolated transplantation of insulin-producing cells under the direction of Professor Tejal A. Desai. While in graduate school, Dr. Mendelsohn served as the director for the Venture Innovation Program in Life Sciences, and completed his certificate in Management of Technology with the Haas School of Business.

Dr. Mendelsohn has served as a Technical Advisor to the Alfred E. Mann Institute for Biomedical Engineering at USC, a fellow of the Startup Leadership Program, the President of UCSF’s Graduate Division Alumni Association, and is currently a board member of the Maestro Foundation.

Aaron mendelsohn

Aaron Mendelsohn, J.D.

Director

Mr. Mendelsohn has been involved in financing in the medical field, including several Al Mann companies such as MiniMed, MRG, and Advanced Bionics. He is a founder and, since its inception, has been a director for Second Sight Medical Products, a publicly traded company which developed and commercialized the world's first prosthetic retinal stimulator that restores some useful vision to the profoundly blind. He served as a director of MRG from its formation in 1998 until it was sold in 2001 to Medtronic, Inc. He served on the board of Advanced Bionics for many years until it was sold to Boston Scientific in 2004. He served as a director of the Alfred Mann Institute for Biomedical Engineering at USC from its inception in 1998 until after Al’s death in 2016. During that time, he was a member of the 3-man committee that served as the CEO. He is a founder of Mastacopia, S.A., a start-up company which has developed a new and better method of breast cancer screening currently in testing at a Harvard University hospital

Mr. Mendelsohn also is a founder and has served as Chairman of the Maestro Foundation since it was organized in 1983. The Maestro foundation is a leading non-profit musical philanthropic organization which hosts what is considered to be the nation’s premier chamber music series and has an active instrument lending program which lends approximately 100 professional-level string instruments and bows to young, career-bound classical musicians. Mr. Mendelsohn holds a Bachelor’s Degree with honors from UCLA and holds a JD from Loyola University School of Law.

Dean baker

Dean Baker, Ph.D.

Director

Dr. Baker served on the board of directors of Advanced Bionics prior to its sale to Boston Scientific, was the founding director of the Alfred E. Mann Institute for Biomedical Engineering at USC, and served for 9 years on the board of directors (including serving on compensation, audit, and governance committees) for Semtech, a publicly traded semiconductor company. He currently serves on the board of directors for Transonic Imaging, a medical imaging startup.

Dr. Baker was also a vice president of Northrop Grumman for 16 years, overseeing a division with $1 billion in annual sales. Dr. Baker has continued to advise Nano Precision Medical in intellectual property, compensation, capitalization, and operation issues.

Gregg williams

Gregg Williams

Director

Gregg Williams is the Chairman, President and Chief Executive Officer of Williams International Co., LLC , the world’s leading producer of small fanjet engines for business jet and defense applications. Prior to his current assignment at Williams International, Mr. Williams held several key managerial positions within the company including serving as its President & Chief Operating Officer, Vice President, Advanced Technology, Director, Program Management and Director, Engineering. He received a Bachelor of Science degree in mechanical engineering from the University of Utah and holds numerous patents related to gas turbine engines, turbo machinery, rocket engines and engine control systems.

Mr. Williams is also the Chairman of the board and largest shareholder of Second Sight Medical Products , a publicly traded company (NASDAQ: EYES) dedicated to defeating blindness by developing and commercializing implantable visual prostheses. In addition, Mr. Williams is Chairman and majority owner of Ramos Arizpe Manufacturing (www.ram-mx.com) an automotive engine parts manufacturing company located in Mexico. He also serves on the Board of Directors of the General Aviation Manufacturers Association, is a past member of the Young Presidents Organization, and a former member of Henry Ford Health System’s board of trustees. Gregg is an active pilot with multiengine, instrument and seaplane ratings.